Logo image of BA

BOEING CO/THE (BA) Stock Fundamental Analysis

NYSE:BA - New York Stock Exchange, Inc. - US0970231058 - Common Stock - Currency: USD

226.84  +0.75 (+0.33%)

After market: 231.2 +4.36 (+1.92%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BA. BA was compared to 65 industry peers in the Aerospace & Defense industry. BA may be in some trouble as it scores bad on both profitability and health. BA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year BA has reported negative net income.
BA had a negative operating cash flow in the past year.
In the past 5 years BA always reported negative net income.
In multiple years BA reported negative operating cash flow during the last 5 years.
BA Yearly Net Income VS EBIT VS OCF VS FCFBA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B -10B

1.2 Ratios

BA has a worse Return On Assets (-7.45%) than 70.77% of its industry peers.
Industry RankSector Rank
ROA -7.45%
ROE N/A
ROIC N/A
ROA(3y)-4.27%
ROA(5y)-4.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BA Yearly ROA, ROE, ROICBA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BA Yearly Profit, Operating, Gross MarginsBA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1

2. Health

2.1 Basic Checks

BA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BA has been increased compared to 1 year ago.
The number of shares outstanding for BA has been increased compared to 5 years ago.
Compared to 1 year ago, BA has an improved debt to assets ratio.
BA Yearly Shares OutstandingBA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BA Yearly Total Debt VS Total AssetsBA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

Based on the Altman-Z score of 1.19, we must say that BA is in the distress zone and has some risk of bankruptcy.
BA has a Altman-Z score of 1.19. This is amonst the worse of the industry: BA underperforms 81.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACCN/A
WACC9.96%
BA Yearly LT Debt VS Equity VS FCFBA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

BA has a Current Ratio of 1.23. This is a normal value and indicates that BA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BA (1.23) is worse than 72.31% of its industry peers.
BA has a Quick Ratio of 1.23. This is a bad value and indicates that BA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.37, BA is doing worse than 93.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.37
BA Yearly Current Assets VS Current LiabilitesBA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

3

3. Growth

3.1 Past

BA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -247.36%.
The Revenue has decreased by -9.15% in the past year.
Measured over the past years, BA shows a decrease in Revenue. The Revenue has been decreasing by -4.74% on average per year.
EPS 1Y (TTM)-247.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.64%
Revenue 1Y (TTM)-9.15%
Revenue growth 3Y2.21%
Revenue growth 5Y-4.74%
Sales Q2Q%17.67%

3.2 Future

The Earnings Per Share is expected to grow by 20.17% on average over the next years. This is a very strong growth
BA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.30% yearly.
EPS Next Y91.1%
EPS Next 2Y47.72%
EPS Next 3Y32.64%
EPS Next 5Y20.17%
Revenue Next Year25.38%
Revenue Next 2Y20.52%
Revenue Next 3Y17.13%
Revenue Next 5Y14.3%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BA Yearly Revenue VS EstimatesBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50B 100B 150B
BA Yearly EPS VS EstimatesBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 -20

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BA. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 61.13 indicates a quite expensive valuation of BA.
BA's Price/Forward Earnings ratio is in line with the industry average.
BA is valuated expensively when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 61.13
BA Price Earnings VS Forward Price EarningsBA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BA Per share dataBA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BA's earnings are expected to grow with 32.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.72%
EPS Next 3Y32.64%

0

5. Dividend

5.1 Amount

No dividends for BA!.
Industry RankSector Rank
Dividend Yield N/A

BOEING CO/THE

NYSE:BA (7/11/2025, 8:04:00 PM)

After market: 231.2 +4.36 (+1.92%)

226.84

+0.75 (+0.33%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)04-23 2025-04-23/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners74.46%
Inst Owner Change0%
Ins Owners0.03%
Ins Owner Change4.18%
Market Cap171.04B
Analysts82.78
Price Target228.58 (0.77%)
Short Float %2.12%
Short Ratio1.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.94%
Min EPS beat(2)-91.07%
Max EPS beat(2)63.2%
EPS beat(4)2
Avg EPS beat(4)-16.75%
Min EPS beat(4)-91.07%
Max EPS beat(4)63.2%
EPS beat(8)5
Avg EPS beat(8)2.53%
EPS beat(12)5
Avg EPS beat(12)-793.15%
EPS beat(16)6
Avg EPS beat(16)-758.16%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-8.71%
Max Revenue beat(2)-2.69%
Revenue beat(4)0
Avg Revenue beat(4)-4.79%
Min Revenue beat(4)-8.71%
Max Revenue beat(4)-2.69%
Revenue beat(8)2
Avg Revenue beat(8)-2.15%
Revenue beat(12)2
Avg Revenue beat(12)-3.63%
Revenue beat(16)2
Avg Revenue beat(16)-5.09%
PT rev (1m)4.63%
PT rev (3m)12%
EPS NQ rev (1m)-25.68%
EPS NQ rev (3m)-75.98%
EPS NY rev (1m)-7.33%
EPS NY rev (3m)6.08%
Revenue NQ rev (1m)5.95%
Revenue NQ rev (3m)3.87%
Revenue NY rev (1m)1.16%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 61.13
P/S 2.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.73
EYN/A
EPS(NY)3.71
Fwd EY1.64%
FCF(TTM)-16.92
FCFYN/A
OCF(TTM)-13.71
OCFYN/A
SpS92.1
BVpS-4.41
TBVpS-17.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.27%
ROA(5y)-4.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 130.38%
Cap/Sales 3.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 0.37
Altman-Z 1.19
F-Score3
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)90.02%
Cap/Depr(5y)74.76%
Cap/Sales(3y)2.43%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.64%
EPS Next Y91.1%
EPS Next 2Y47.72%
EPS Next 3Y32.64%
EPS Next 5Y20.17%
Revenue 1Y (TTM)-9.15%
Revenue growth 3Y2.21%
Revenue growth 5Y-4.74%
Sales Q2Q%17.67%
Revenue Next Year25.38%
Revenue Next 2Y20.52%
Revenue Next 3Y17.13%
Revenue Next 5Y14.3%
EBIT growth 1Y-1098.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.79%
EBIT Next 3Y49.92%
EBIT Next 5Y32.37%
FCF growth 1Y-351.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-261.22%
OCF growth 3YN/A
OCF growth 5YN/A